S'abonner

Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study - 05/09/19

Doi : 10.1016/S1470-2045(19)30389-4 
Michael Höckel, ProfMD a, f, g, , Benjamin Wolf, MD b, Katja Schmidt, RN c, Meinhard Mende, PhD d, Bahriye Aktas, ProfMD b, Rainer Kimmig, ProfMD f, Nadja Dornhöfer, MD b, Lars-Christian Horn, ProfessorMD e
a Leipzig School of Radical Pelvic Surgery, University of Leipzig, Leipzig, Germany 
b Department of Gynecology and Obstetrics, University of Leipzig, Leipzig, Germany 
c Institute of Anatomy, University of Leipzig, Leipzig, Germany 
d Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany 
e Division of Breast, Gynecological and Perinatal Pathology, University of Leipzig, Leipzig, Germany 
f Department of Gynecology and Obstetrics, University of Essen, Essen, Germany 
g Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany 

* Correspondence to: Prof Michael Höckel, Leipzig School of Radical Pelvic Surgery, University of Leipzig, Leipzig 04103, Germany Leipzig School of Radical Pelvic Surgery University of Leipzig Leipzig 04103 Germany

Summary

Background

Previous findings from our centre suggest that carcinoma of the cervix propagates within ontogenetic cancer fields, tissue compartments defined by staged morphogenesis. We aimed to determine whether surgical treatment that accounts for stage-associated, ontogenetic cancer fields and their associated lymphoid tissues results in locoregional tumour control without the need for adjuvant radiotherapy.

Methods

We did the final clinical and histopathological evaluation of data from, the single-centre, observational, cohort study, the Leipzig School Mesometrial Resection Study. Patients of any age with stage IB1, IB2, IIA1, IIA2, or IIB cervical cancer (according to 2009 International Federation of Gynecology and Obstetrics [FIGO]) had total mesometrial resection or extended mesometrial resection and therapeutic lymph node dissection, done on the basis of ontogenetic cancer fields. We defined sentinel node, first-line, second-line, and third-line lymph node regions as progressive regional cancer fields. Primary outcomes were disease-specific survival and recurrence-free survival, and treatment-related morbidity (assessed with the Franco-Italian glossary). Applying Cox proportional hazard models, ontogenetic local (T) and regional (N) tumour staging was compared with pathological T and N staging. This trial is registered with the German Clinical Trials Register, number DRKS00015171.

Findings

Between Oct 16, 1999, and June 27, 2017, 523 patients were treated per protocol and followed up for a median of 61·8 months (IQR 49·3–94·8). In 495 patients with cervical cancer treated with cancer field surgery, 5-year disease-specific survival was 89·4% (95% CI 86·5–92·4) and recurrence-free survival was 83·1% (79·7–86·6). In the per-protocol population of 523 patients, treatment-related morbidity comprised 112 (21%) grade 2 and 15 (3%) grade 3 complications. The most common moderate and severe treatment-related complications and sequelae were wound dehiscence (17 [3%]), hydronephrosis (17 [3%]), bowel obstruction (26 [5%]), and lymph oedema (33 [6%]). One patient (<1%), who received total mesometrial resection, died from postoperative brain infarction.

Interpretation

Total or extended mesometrial resection with therapeutic lymph node dissection based on ontogenetic cancer fields results in good survival outcomes of patients with cervical cancer in our institution, but needs to be investigated further in multicentre trials.

Funding

Leipzig School of Radical Pelvic Surgery, University of Leipzig Medical School, and the Gynecologic Oncology Research Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2019  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 9

P. 1316-1326 - septembre 2019 Retour au numéro
Article précédent Article précédent
  • Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
  • Michael Friedlander, Tarek Meniawy, Ben Markman, Linda Mileshkin, Paul Harnett, Michael Millward, Joanne Lundy, Alison Freimund, Christie Norris, Song Mu, John Wu, Virginia Paton, Bo Gao
| Article suivant Article suivant
  • Cancer control in the Pacific: big challenges facing small island states
  • Diana Sarfati, Rachel Dyer, Filipina Amosa-Lei Sam, Michael Barton, Freddie Bray, Eka Buadromo, Alec Ekeroma, Sunia Foliaki, James Fong, Josephine Herman, Linda Huggins, Kiki Maoate, Ineke Meredith, Glen Mola, Neal Palafox, Viliami Puloka, Hai-Rim Shin, Jane Skeen, Wendy Snowdon, Malama Tafuna’i, Andrea Teng, David Watters, Paula Vivili

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.